Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Vet Comp Oncol ; 13(4): 409-23, 2015 Dec.
Article in English | MEDLINE | ID: mdl-24007303

ABSTRACT

Stereotactic radiosurgery (SRS) is a procedure that delivers a single large radiation dose to a well-defined target. Here, we describe a frameless SRS technique suitable for intracranial targets in canines. Medical records of dogs diagnosed with a primary intracranial tumour by imaging or histopathology that underwent SRS were retrospectively reviewed. Frameless SRS was used successfully to treat tumours in 51 dogs with a variety of head sizes and shapes. Tumours diagnosed included 38 meningiomas, 4 pituitary tumours, 4 trigeminal nerve tumours, 3 gliomas, 1 histiocytic sarcoma and 1 choroid plexus tumour. Median survival time was 399 days for all tumours and for dogs with meningiomas; cause-specific survival was 493 days for both cohorts. Acute grade III central nervous system toxicity (altered mentation) occurred in two dogs. Frameless SRS resulted in survival times comparable to conventional radiation therapy, but with fewer acute adverse effects and only a single anaesthetic episode required for therapy.


Subject(s)
Brain Neoplasms/veterinary , Dog Diseases/surgery , Radiosurgery/veterinary , Animals , Brain Neoplasms/mortality , Brain Neoplasms/surgery , Cranial Nerve Neoplasms/mortality , Cranial Nerve Neoplasms/surgery , Cranial Nerve Neoplasms/veterinary , Dog Diseases/mortality , Dogs , Female , Male , Meningioma/mortality , Meningioma/surgery , Meningioma/veterinary , Pituitary Neoplasms/mortality , Pituitary Neoplasms/surgery , Pituitary Neoplasms/veterinary , Radiosurgery/methods , Retrospective Studies , Survival Analysis , Trigeminal Nerve Diseases/mortality , Trigeminal Nerve Diseases/surgery , Trigeminal Nerve Diseases/veterinary
2.
Vet Comp Oncol ; 9(3): 232-40, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21848626

ABSTRACT

Understanding the inherent radiosensitivity and repair capacity of canine transitional cell carcinoma (TCC) can aid in optimizing radiation protocols to treat this disease. The objective of this study was to evaluate the parameters surviving fraction at 2 Gy (SF(2) ), α/ß ratio and capacity for sublethal damage repair (SLDR) in response to radiation. Dose-response and split-dose studies were performed using the clonogenic assay. The mean SF(2) for three established TCC cell lines was high at 0.61. All the three cell lines exhibited a low to moderate α/ß ratio, with the mean being 3.27. Two cell lines exhibited statistically increased survival at 4 and 24 h in the dose-response assay. Overall, our results indicate that the cell lines are moderately radioresistant, have a high repair capacity and behave similarly to a late-responding normal tissue. These findings indicate that the radiation protocols utilizing higher doses with less fractionation may be more effective for treating TCC.


Subject(s)
Carcinoma, Transitional Cell/veterinary , Dog Diseases/radiotherapy , Urologic Neoplasms/veterinary , Animals , Carcinoma, Transitional Cell/pathology , Carcinoma, Transitional Cell/radiotherapy , Cell Line, Tumor , Dog Diseases/pathology , Dogs , Dose Fractionation, Radiation , Dose-Response Relationship, Radiation , Radiation Tolerance , Urologic Neoplasms/pathology , Urologic Neoplasms/radiotherapy
3.
J Vet Intern Med ; 23(5): 1064-70, 2009.
Article in English | MEDLINE | ID: mdl-19627472

ABSTRACT

BACKGROUND: Sequential half-body irradiation (HBI) combined with chemotherapy is feasible in treating canine lymphoma, but prolonged interradiation intervals may affect efficacy. A 2-week interradiation interval is possible in most dogs receiving low-dose rate irradiation (LDRI) protocols at 6 Gy dose levels. HYPOTHESIS: LDRI incorporated into a cyclophosphamide, doxorubicin, vincritine, and prednisone (CHOP)-based chemotherapy protocol is effective for the treatment of lymphoma in dogs. ANIMALS: Thirty-eight client-owned animals diagnosed with multicentric lymphoma. METHODS: Retrospective study evaluating the efficacy and prognostic factors for the treatment of canine lymphoma with sequential HBI and chemotherapy. RESULTS: The median 1st remission was 410 days (95% confidence interval [CI] 241-803 days). The 1-, 2-, and 3-year 1st remission rates were 54, 42, and 31%. The median overall survival was 684 days (95% CI 334-1,223 days). The 1-, 2-, and 3-year survival rates were 66, 47, and 44%. CONCLUSIONS AND CLINICAL RELEVANCE: Results of this study suggest that treatment intensification by a 2-week interradiation treatment interval coupled with interradiation chemotherapy is an effective treatment for dogs with lymphoma.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Dog Diseases/drug therapy , Dog Diseases/radiotherapy , Lymphoma/veterinary , Animals , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Cyclophosphamide/adverse effects , Dog Diseases/pathology , Dogs , Dose-Response Relationship, Radiation , Doxorubicin/administration & dosage , Doxorubicin/adverse effects , Female , Hematocrit/veterinary , Hemibody Irradiation/methods , Hemibody Irradiation/veterinary , Immunophenotyping/veterinary , Kaplan-Meier Estimate , Lymphoma/drug therapy , Lymphoma/pathology , Lymphoma/radiotherapy , Male , Prednisone/administration & dosage , Prednisone/adverse effects , Retrospective Studies , Vincristine/administration & dosage , Vincristine/adverse effects
4.
Vet Comp Oncol ; 6(4): 257-67, 2008 Dec.
Article in English | MEDLINE | ID: mdl-19178684

ABSTRACT

Thirteen dogs with previously untreated multicentric lymphoma were enrolled in a prospective study investigating the effects of low-dose rate total body irradiation (TBI) and chemotherapy. Dogs received either 6 or 8 Gy TBI in half-body fractions, 2 weeks apart. Toxicity consisted of mild to moderate haematological and gastrointestinal (GI) signs. One dog died from treatment complications. Anorexia was noted independent of dose. Haematological toxicity was more common and more severe after 8 Gy treatment. GI toxicity was more likely postcaudal half-body irradiation with 8 Gy. Other than leukotrichia, late effects from radiation were not observed. Results indicated that haematological and nonhaematological toxicity was dose dependent. However, the protocol was well tolerated and treatment intensification using a 2-week inter-radiation interval was possible in all dogs treated with 6 Gy. Preliminary survival data for these dogs were very encouraging, providing a strong rationale to analyse the efficacy of low-dose rate irradiation (LDRI) in canine lymphoma.


Subject(s)
Antineoplastic Agents/therapeutic use , Dog Diseases/drug therapy , Dog Diseases/radiotherapy , Hemibody Irradiation/veterinary , Lymphoma/veterinary , Animals , Dogs , Dose-Response Relationship, Immunologic , Female , Hemibody Irradiation/adverse effects , Lymphoma/drug therapy , Lymphoma/radiotherapy , Male , Radiation Injuries
5.
Vet Comp Oncol ; 5(4): 197-207, 2007 Dec.
Article in English | MEDLINE | ID: mdl-19754778

ABSTRACT

Acute radiation-induced dermatitis (ARID) is a common sequela of radiation therapy in dogs. There is no consensus regarding ARID management in human medicine and the standard of care in veterinary medicine has not been reported. The objective was to report the practice standards for ARID management in dogs in North America. The design used was a questionnaire survey. Fifty-eight private and university teaching veterinary hospitals were contacted, 54 participated. The topical and oral medications used to treat ARID, prevent or treat bacterial infection, control pain and the indications for and timing of treatment initiation were the outcome measures. A minority of facilities (4/54, 7.5%) use exactly the same protocol regarding all parameters. There was agreement (>75% of facilities) with respect to the general use of oral antibiotics (77.8%), the need for pain control (92.6%) and the use of tramadol for pain control (76%), although the details of their use varied widely. There is a divergence of opinions regarding all details of ARID management in dogs except the general use of oral antibiotics and pain control medications.

6.
Vet Comp Oncol ; 2(3): 171-5, 2004 Sep.
Article in English | MEDLINE | ID: mdl-19379305

ABSTRACT

The boxer breed of dog is at high risk for a variety of neoplasms including lymphoma. In this observational study, tissue sections from boxer dogs with lymphoma were immunostained for T and B lymphocyte distinction, and the results compared with similar studies carried out on lymphoma tissues from temporally selected cohorts of golden retriever and rottweiler dogs. The frequency of T-cell lymphomas was significantly (P < 0.001 for all comparisons) higher in the boxers than in the rottweilers or golden retrievers. We are unaware of other reports linking immunotype of canine lymphoma with breed; whether other brachycephalic breeds of dogs have a similar preponderance of T-cell lymphoma awaits further study.

SELECTION OF CITATIONS
SEARCH DETAIL
...